High-throughput Drug Sensitivity analysis strategy (HDS)
Right Patient. Right Dose. Right Drug. —Makes Precision Medicine Possible！
High-throughput Drug Sensitivity analysis strategy (HDS)
HDS combines 2D primary cell-based and 3D organoid-based drug sensitivity testing to provide comprehensive drug response profiling for cancer patients. Using fresh surgical specimens, pleural/ascitic effusions (solid tumors), or bone marrow/peripheral blood (hematologic malignancies), along with our proprietary primary cell isolation and enrichment technologies, the platform delivers actionable testing reports within 7–14 days. All testing is conducted at Hefei PreceDo Medical Laboratory Co., Ltd.
Key Advantages
Comprehensive Coverage:
Drug response profiling for patients across all disease stages
Rapid Turnaround:
Results within 7–14 days
Personalized Testing
Customized drug selection, dosage, and combination strategies based on individual patient needs.
Clinical Value
For newly diagnosed patients, we help eliminate ineffective treatment options, narrowing the selection and identifying potentially effective therapies.
Who Can Benefit
Newly Diagnosed:
Eliminate ineffective drugs, identify effective options
Relapsed/Refractory:
Expand screening, find effective treatments when none are left
Indications
Hematologic malignancies, lung, liver, ovarian, triple-negative breast, esophageal, gastric, colorectal, and more.
Reprogramming Cells, Empowering Medicine
©2026 PRECEDO Biotechnology Co., Ltd. Powered by：www.300.cn